1. To establish whether the primary end point was the incidence of hypophosphatemia between baseline and day 35.
2. To determine clinical significance of study results.
06/04/2021 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Mohammed Nasaruddin, MD